Entries |
Document | Title | Date |
20080221190 | High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof - One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75pm by diameter, whereas at least 99% of the particles are below 250 μm by diameter, and process for its preparation. A pharmaceutical composition comprising as active ingredient, high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of | 09-11-2008 |
20080300290 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments - Compounds of general formula (I) | 12-04-2008 |
20090143452 | Use of prochloraz for wood protection - The active compound prochloraz and fungicidal compositions based on prochloraz are highly suitable for protecting wood and timber products against attack and/or destruction by soft-rot fungi. | 06-04-2009 |
20090247600 | REMEDY FOR CORNEAL DISEASES - A therapeutic agent for a corneal disease comprising ozagrel or a salt thereof as an active ingredient is provided. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient. | 10-01-2009 |
20090286841 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 11-19-2009 |
20100076043 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE - There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. Also provided are compositions for increasing nitric oxide physiological levels in a subject, methods for increasing nitric oxide physiological levels in a subject, methods for improving a subject's muscle strength, athletic performances and/or lean body mass gain and or performance in a subject. | 03-25-2010 |
20100222403 | Micogel Topical Formulations - The present invention encompasses anhydrous micogel formulations containing miconazole and methods of use for the treatment of topical disorders including acne. | 09-02-2010 |
20110039906 | ANTIBACTERIAL COMBINATION THERAPY - There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species. | 02-17-2011 |
20110071204 | PERCUTANEOUS ABSORPTION PREPARATION - This present invention provides a percutaneous absorption type pharmaceutical preparation which includes 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the active ingredient and a backbone for transdermal system, and satisfies at least one of the following conditions (1) and (2). The pharmaceutical preparation of the present invention enables absorption of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide, which has a low ability to be absorbed from the skin, from the skin into the body continuously and efficiently.
| 03-24-2011 |
20110160266 | Novel Anti-Arrhythmia Agent - It has been discovered that SKF-96365 prevents and reverses ectopic activity in myocyte cells, and that SKF-96365 is effective against all types of ectopic activity. Methods are provided using SKF-96365 and its derivatives to prevent and reverse electromechanical disorders of myocytes; these include methods of treatment and prevention of cardiac arrhythmias in human and animal subjects. These further include methods of preventing and reversing arrhythmias in cardiac muscles and hearts. These further include methods of preventing and reversing spontaneous mechanical activity in a myocyte. Pharmaceutical drugs for the treatment and prevention of cardiac arrhythmia are described, based on SKF-96365. Kits for employing the methods are also described. | 06-30-2011 |
20110196006 | IMAZALIL COMPOSITIONS COMPRISING ALKOXYLATED AMINES - The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising the fungicidal compound imazalil. It also relates to formulations comprising imazalil and alkoxylated amines. These formulations are useful to protect materials, plants, fruits or seeds against fungi. | 08-11-2011 |
20110281923 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 11-17-2011 |
20120029041 | 2-ARYL IMIDAZOLINE DERIVATIVES - 2-Aryl imidazoline derivatives are provided that are useful as anti-obesity agents or the like. A compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R | 02-02-2012 |
20120035233 | MEDICINAL CREAM MADE USING MICONAZOLE NITRATE AND CHITOSAN AND A PROCESS TO MAKE THE SAME - The present invention is directed to a composition for treating fungal skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antifungal active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of miconazole nitrate used in treating fungal skin infections, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and an anti fungal agent in the form of miconazole nitrate, are incorporated in cream base for use in treating fungal skin infections with allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition. | 02-09-2012 |
20120083515 | BIOADHESIVE GEL BASED ON HYDROXYETHYLCELLULOSE - Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent. | 04-05-2012 |
20120101139 | Econazole Composition and Methods of Treatment Therewith - The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation. | 04-26-2012 |
20120101140 | Econazole Composition and Methods of Treatment Therewith - The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation. | 04-26-2012 |
20120129906 | MODULATORS OF S1P RECEPTORS - The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-24-2012 |
20130203829 | Mitochondria-Targeted Inhibitors of Cytochrome C Peroxidase for Protection from Apoptosis - The present application is directed to novel imidazole-substituted fatty acids that have been functionalized with an alkyl triphenylphosphonium group, compositions comprising these compounds and their use as inhibitors of cytochrome c peroxidase, in particular for the treatment and prevention of apoptosis. | 08-08-2013 |
20130274306 | TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS - The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity. | 10-17-2013 |
20130345276 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE - The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis. | 12-26-2013 |
20140275198 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES OR FATTY LIVER CONTAINING A CYP4A INHIBITOR AS AN ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver. | 09-18-2014 |
20150306006 | SCALP CARE COMPOSITION - A scalp care composition directed to a scalp care composition comprising from about 0.05% to about 5% of an anti-dandruff active, from about 0.1% to about 25% of one or more organic solvents, from about 1% to about 99% of a volatile carrier wherein the anti-dandruff active is soluble in the scalp care composition. | 10-29-2015 |
20160081907 | FORMULATION COMPRISING LIQUID ESTER QUATS AND/OR IMIDAZOLINIUM SALTS AND POLYMER THICKENERS - The invention relates to formulations containing liquid ester quats and/or imidazolinium salts and polymer thickeners and to the use thereof. | 03-24-2016 |
20160128982 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - Antimicrobial compositions include at least one antimicrobial azole compound, particularly imidazole, triazole or thiazole compounds, and at least one polymeric biguanide compound. The compositions are useful in treating or preventing microbial infections of the skin and epithelial lined body cavities, such as ears. | 05-12-2016 |